Summary
The purpose of this article is to review the literature on the pharrnacoeconomics and quality of life of therapy interventions for patients with peripheral vascular disorders . The paper is in 4 parts. The first presents a framework for the analysis of such drug interventions, which contrasts studies that have a clinical focus with those that take a system or modelling focus and presents a research typology for studies in this area. The second part ofthe paper reviews pharmacoeconomic studies of selected interventions and assesses their contribution to decision-making within healthcare systems. The particular focus is on the pharmacoeconomics of therapy for atherosclerosis . While there are no studies which have evaluated the overall costs o f treatment in this disease area or considered the cost effectiveness of the range of alternative treatment strategies, the issues of good clinical practice and the implicit cost effectiveness of identifying patients for treatment options and prevention strategies has been addressed . The few studies which have considered the cost consequences of particular intervention strategies, specifically pentoxifylline therapy and surgical options, are limited in scope and are difficult to generalise due to their age, their study design or the treating environment from which data are drawn. The third part reviews quality-of-life studies and, once again, assesses their contribution to formulary decision-making. There are no published studies which have compared quality-of-Iife outcomes associated with alternative treatment approaches or which have reported changes associated with pharmacotherapy in patients with peripheral vascular disorders. Finally, given the dearth of studies in this area, a research agenda is proposed for ongoing investigations.
The term 'peripheral vascular disorder' (PVD) covers the spectrum beginning with any disease of the blood vessels, other than the heart and thoracic aorta, through any disease of the lymph vessels, and ending at peripheral vascular disease of the extremities. The latter category includes venous disorders and disease resulting from occlusion and arterial vasospasm.
This review concentrates on peripheral vascular disease of the extremities, excluding venous disorders and deep vein thrombosis. Our definition of PVD is, therefore, restricted to arteriosclerosis (chronic occlusive arterial disease) thromboangiitis (Buerger's or von Winiwerter's disease) and Raynaud's disease.
Methodology
Any review and assessment of the existing literature in an empirical area must reflect the standards and techniques of analysis that are generally accepted by practitioners. However, the reviewer must also consider whether or not these techniques are useful, in both analytical terms and in their ability to provide decision-makers with relevant information.
In the field of pharmacoeconomics, we are seeing what some have described as a paradigm shift, in which the traditional emphasis on clinically focused, partial economic evaluations is being overtaken by what may be described as a more general, systems approach. This is particularly true in the US, where there is access to large health-system claims databases, although to date there do not appear to be any studies which have used such data to evaluate the costs of treating PVD in health systems.
Types of Study

Clinical Economic Studies
These studies follow the traditional costassignment or ratio approach to pharmacoeconomics. That is, the study is narrowly focused, often deriving from a clinical trial or a retrospective eval-uation of a small group of patients (in many, if not the majority, by chart review), with the objective of deriving a ratio measure or simple cost-outcomes comparison.
Ratio measures would include cost-effectiveness estimates of alternative treatment arms. The more sophisticated studies attempt to assess incremental cost-effectiveness ratios and/or consider the costrelated consequences of particular interventions.
Typically, authors have not considered powering their sample sizes for pharmacoeconomic evaluations (i.e. cost or cost-outcomes ratio comparisons), and economics only enters into the analysis as a simple adding-up of the resources used, in order to generate an estimate of the cost of therapy (or, in a minority of studies, in the application of contingent valuation techniques to estimate the outcomes of particular interventions).
Broader Systems-Based Studies
Studies that take a more broadly based systems perspective are, in most areas of pharmacoeconomics, conspicuous by their absence. Such studies would take the perspective of the health system as a whole. They would attempt to generate an overall or global estimate of the impact of introducing a new therapy, or switching existing therapies, on the profile of cost and outcomes in a disease or treatment area. Explicit recognition would be taken of: (i) treatment protocols; (ii) the characteristics of the patients being treated; (iii) the cost structures that support therapy interventions (e.g. constant or increasing/decreasing costs); and (iv) the impact of therapy switching on the outcomes profiles of the treated population.
A systems perspective would be, for example, a principal focus in the assessment of disease management, in establishing targets for disease-management interventions (resource savings, outcomes to be achieved), as well as providing the necessary information for the negotiation and implementation of disease-management contracts.
While recognising the limitations of pharmacoeconomic studies that derive from (or piggy-back on) randomised clinical trials, some authors have opted for a modified clinical perspective suggesting that the future of pharmacoeconomics lies in 'naturalistic' trials. That is. economic evaluations are undertaken in trials in which patients are selected to represent the anticipated treated population.
The systems approach could make use of naturalistic trials, but would emphasise the need to mo-del disease interventions and to draw data from a range of sources (claims databases as well as clinical and naturalistic trials). The point is that. with a systems perspective, we are concerned with the impact of new therapies in a given treatment area and the impact of therapy switching (not therapy comparisons) on costs and outcomes profiles.
Resources and Prices
In pharmacoeconomic studies, it is important to distinguish the resources that are utilised to support therapy. and the price that applies to those resources. The majority of (if not all) pharmacoeconomic studies assume that there is no relationship between relative prices and resource utilisation (assuming completely inelastic demand or a fixed coefficients production function) . This is an issue that has yet to be explored. However. from a resourceallocation perspective, it is often argued that the unit prices chosen should renect market prices.
While this approach is entirely appropriate. care must be taken in interpreting cost-outcomes ratios in the prices chosen and in the context of the US, where there is an important distinction between costs and charges: the latter (such as the fee charged for Medicare or Medicaid patients) may bear no relation at all to the cost to the health system. For example. anecdotal evidence suggests that the actual average cost to a managed-care organisation for treating a patient with AIDS may be only a third of the amount that Medicaid reimburses. It is for this reason that there is often reluctance to quote the actual price differentials achieved in costing disease interventions.
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costs to a managed-care system rather than Medicare reimbursement can lead to significant cost differences. a situation that is made all the more difficult to interpret if the study is not powered for differences in resource utilisation and consequent cost differences. This situation is further compounded when a managed care organisation may cover service providers under a range of different contractual arrangements, ranging from feefor-service, through capitation to staff model arrangements. As fee-for-service costs (or amounts reimbursed) are the only true market prices, care has to be taken in interpreting imputed costs (e.g. through a resource-based relative value scale) of resource utilisation and service provision.
In our discussion of the pharmacoeconomics of, and quality-of-life (QOL) issues relating to, PVD, we will consider the contributions of the various studies in terms of evaluating therapy intervention areas. This involves a brief review of the disease and therapy options, and a review of the relevant literature.
Peripheral Vascular Disorders
PVDs can be broadly classified into 2. categories: arterial and venous. the latter being excluded from this review. In the arterial category, these disorders can be either obstructive or vasospastic: the obstructive group includes diseases such as atherosclerosis and thromboangiitis. whereas Raynaud's disease belongs to the vasospastic group.
In reviewing the peripheral arterial disease (PAD) literature, which is quite limited. we propose to focus on atherosclerosis. given the total absence of studies that have considered either thromboangiitis or Raynaud's phenomenon.
Within the general area of atherosclerosis therapy, we will consider studies that have reviewed the overall cost effectiveness and/or QOL impact of atherosclerosis and its treatment. We will also examine more specific studies that have considered: (i) drug interventions (pentoxifylline and iloprost); (ii) alternatives to surgical interventions (including drug therapies): and (iii) the cost effectiveness of noninvasive diagnostic testing. While this may seem a disparate assembly, all of these aspects of PAD are properly seen as elements in overall evaluation and treatment strategies. If pharmacological interventions are to be considered, they should be seen in this context.
The Pharmacoeconomlcs of Atherosclerosis
The principal goals of therapy in patients with atherosclerosis are to:
• limit disease progression • improve blood flow • relieve pain • treat or prevent gangrene and ulceration.
The recommended therapy interventions to limit disease progression are control of hyperlipoproteinaemia or associated disease, and abstinence from tobacco. When improving blood flow is the objective and ischaemia is present, or there is intermittent claudication, the appropriate methods are arterial surgery and angioplasty, as well as nonsurgical techniques of improving collateral blood flow.
As far as drug therapy is concerned, there is controversy over using ~-blockers in patients with concurrent coronary artery disease or hypertension, as studies have shown that these agents can exacerbate intermittent claudication. Pentoxifylline has been shown to be of benefit, although there are increasing doubts as to the value of such therapy. There are also a number of studies that have addressed the use of lipid-lowering drug therapy. These are of interest because of the ability of lipid-lowering drugs to prevent primary and secondary atherosclerosis; the results from large-scale trials have demonstrated that there can be a significant reduction in cardiovascular events and procedures with such therapy. It is not our intention to review the lipid-or cholesterol-reducing drug literature -rather to see this as an adjunct to the evaluation of atherosclerosis interventions. There also remains the general issue of am-(J Adis international Um/ted. All rights reserved. Surprisingly, even though atherosclerosis has a reported prevalence of 5% in men over 50 years of age,111 no studies have attempted to trace the course of the disease, evaluated the resources required to support atherosclerosis interventions, or considered the cost effectiveness of alternative intervention strategies. While this situation is likely to change in the near future -at least in the US, with the increasing emphasis on cost containment in health systems and the increasing cost of atherosclerosis interventions -we are currently faced with a number of quite disparate studies. Many of these studies are not only superficial in nature, in that they equate good clinical practice with cost effectiveness, but they are also of limited application because of the time that has passed since they were conducted or the environments within which they were undertaken.
As a first step, we can consider studies that, while nominally addressing the question of cost effectiveness, are more concerned with the issue of 'good' clinical practice, equating this with cost effectiveness. A recent special supplement to the Canadian Journal of Cardiology, has addressed the issue of the cost effectiveness in diagnosis and treatment of atherosclerosis. Two contributions are of interest: first, the consensus report by Frohlich,1 2 1 and second, the article by Superko.131 Frohlich l21 considers 3 elements: (i) who to investigate for atherosclerosis; (ii) how to investigate them; and (iii) the cost effectiveness of potential intervention strategies. The choice of who to investigate for atherosclerosis focuses on those who are symptomatic (coronary artery disease. PVD or cerebral vascular disease) and those who are asymptomatic; but who have a first-degree relative with premature vascular disease or a well-defined metabolic abnormality (e.g. familial hypercholesterolaemia). The choice of investigation strategy involves traditional lipid screening with, after risk-factor assessment, an ECG examination. As to the evaluation of the extent of atherosclerosis, a range of tests are noted, although the only recommendation as to the cost effectiveness of a particular test is the use of a B-mode ultrasound, on the basis that its cost 'is less than several months' worth of drug treatment and follow up for dyslipidemia') 21 Unfortunately, in evaluating the cost effectiveness of alternative interventions, the level of Frohlich's analysisl~1 is more impressionistic rather than being based on any concrete analyses. The term cost effectiveness is seen as synonymous with good clinical practice and the targeting of patients for particular treatment interventions. While there is no doubt that cost effectiveness of atherosclerosis interventions are enhanced by the choice of the 'right' intervention for the designated patient groupPI this does not advance the evaluation of the cost-related consequences of intervention options and the development of efficient clinical guidelines.
Superko's contribution l31 is more substantive. Superko argues, on the basis of secondary evidence from the outcomes of lipid-lowering trials, that both sophisticated primary and secondary strategies for prevention of atherosclerosis are cost effective. That is, if the results of primary prevention lipid-lowering trials are modelled, the relative savings and costs from 'changes in treatment due to changes in cardiovascular events' can be comparedYI These results can then be applied to arteriographic trial results so that the costs and savings of more focused treatment can be evaluated. Superkol3 1 concludes that 'sophisticated lipoprotein disorder diagnosis and focused treatment can reduce clinical events and be more cost effective' in an optimal environment for atherosclerosis regression.
Although the studies that consider the cost effectiveness of atherosclerosis prevention are important in pointing to the need for more focused interventions, they say virtually nothing about the overall costs of therapy and the cost effectiveness of alternative treatment pathways (e.g. invasive I'S noninvasive approaches to treating coronary artery diseasel-l l). While they point, quite clearly. to the , AdlS International Umlted. All rights reserved 229 need for clinical guidelines as a means by which resources may be more efficiently allocated within health systems. they say very little about the outcomes of therapy or what should be the choice of outcomes targets in disease interventions. Guidelines usually require physicians to evaluate patients on a common basis. or to evaluate patients with particular characteristics or risk factors that are identified by the health system, and allocated to particular interventions under a care or diseasemanagement programme. These studies provide little guidance as to the cost effectiveness of alternative treatment pathways.
1.2 Penfoxifylline Therapy
Current medical opinion would view pentoxifylline therapy as problematic. Indeed, from a pharmacoeconomic standpoint, no studies have compared the role of pentoxifylline therapy with that of surgery or other drugs. The only studies that have appeared have contrasted subtherapeutic with therapeutic dosages.
Although limited by sample size and by the fact that the study was based at a health maintenance organisation (HMO). the study by Stergachis et al. 151 of the cost effectiveness of pentoxifylline therapy is one of the more useful contributions to the literature on the pharmacoeconomics of treatment of PVDs. This study is important because of its research design and the use of HMO-sourced patient records as control data.
Over a 2-year period. the resource utilisation patterns of 2 groups of patients treated with pentoxifylline for peripheral artery disease were compared hy Stergachis et alYI Those who received (for up to an initial 120 days) a therapeutically efficacious dosage regimen were compared with the group of patients who. from pharmacy records. were identified as having received a subefficacious dose. In contrasting the post-therapy resource utilisation patterns of these 2 groups. the authors concluded that while therapeutic regimens reduced the incidence of related invasive therapeutic and diagnostic procedures. compared with the sUbtherapeutic regimens. in the fIrst year of follow-up, no statistically significant differences were observed in the average or median costs of care. While this may appear a surprising result -with the study authors lSI hinting at a lower (but nonsignificant) adjusted cost -the study was based on an extremely small sample; the study authors, lSI given that it was a retrospective study, apparently made no attempt to power the sample size for a minimum cost differential. They present a reformulation of the cost structures, specifically the medical cost savings, together with a sensitivity analysis. They conclude, using Medicare charges rather than Stergachis et aI. 's cost estimates,ISJ that therapeutically efficacious pentoxifylline therapy can reduce average hospital costs per patient by $US 1173 per year (1991 prices). While Neels et al. 's studyl6J is of some interest, the need for a reformulation may be questioned when it seems clear from the results presented by Stergachis et al. 151 that the failure to find a statistically significant cost difference is not the result of any perceived flaw in their costing methodology, but is attributable to a lack of statistical power.
SUrgicallnteNention. and Optlonl
A few studies have considered the cost consequences and cost effectiveness of surgical interventions in patients with PAD. For example, Jeans et al. l71 have presented results on the comparative costs of vascular surgery versus those of balloon dilation in patients with lower limb ischaemic disease. They found that, at the Bristol Royal Infirmary, UK, the mean cost of angiography and surgery was 5.23 times higher than the cost of angiography and dilation. The principal factor in the cost difference was identified as shorter hospital stay, in addition to fewer staff requirements and the avoidance of general anaesthesia with angio-graphy and dilatation. Similar cost-ratio results have been reported in the US.11l1 While these studies are of interest, they are limited to evaluating the costs of these interventions rather than their cost etTecti veness.
A number of studies have examined the cost effectiveness of arterial reconstruction versus amputation in patients with lower limb ischaemia. One of the more interesting of these studies was presented by Gupta et aI. 19J in their examination of the long term cost factors in limb-threatening ischaemia. In their study,19J estimates were presented (now very much dated) of mean per patient cost for arterial reconstructions, and the principal cost drivers were identified (Le. presence of gangrene, age >70 years and previous bypass surgery). In contrasting a policy of aggressive arterial reconstruction with the alternative of primary amputation, they found that neither the costs nor the functional benefits at I year were different for the 2 groups (see also Veith et al.,IIOI Mackey et al.lll[ and Gregg I12J ), which have considered similar strategies.
A more recent study in New Zealand of patients with lower limb ischaemia compared the economic costs of amputation versus those of intravenous treatment with iloprost.[1[ From a retrospective study of patient records, the hospital costs, costs of prostheses and indirect costs of amputations were determined. These costs were contrasted with the implied costs and outcomes of intravenous iloprost therapy for those patients in whom revascularisation was not possible or had failed. I1oprost was contrasted with amputations in per patient cost terms to generate a break-even ratio, given the cost of iloprost therapy (under 20-and 24-day administration regimens). Unfortunately, according to the data presented in this study,111 it was impossible to make conclusions about the relative cost effectiveness of the 2 therapies. All that could be said was that for iloprost to be at least as cost effective as amputation, the success rate (defined in terms of rate of amputations avoided) must be in the range of 55 to 66% (to give break-even costs). Until more data become available the extent to which a switch to iloprost is likely to occur is unknown . Given that data are available on outcomes with iloprost therapy (e.g. mortality and amputation rates), it is disappointing that the authors did not extend their analysis to modelling the cost effectiveness of iloprost in the New Zealand healthcare system .
Of course, to the extent that there may be no difference between iloprost and placebo in other treating environments, such as the US, these results would only be of local interest.
. 1.Tests and Evaluations
The issue of the choice between noninvasive vascular diagnostic tests is an important one, given the resource implications and costs of many of these procedures. In examining the questions of choice of test, who should be tested and the costs of such tests. Barnes l131 has reviewed the reasons why tests are ordered by physicians and the indic ations for such tests. In pointing to the number of papers on the cost effectiveness of noninvasi ve tests for PAD that have been published (29 between 1966 and 1993), Barnesl!:11 argues that we need to review the cost effectiveness of the various diagnostic tests, ensure that the test is appropriate, and require physicians to justify their choice of test (together with an appropriate pricing or reimbursement structure ).
Given the evidence available, Barnes l131 proposes a range of categories for noninvasive vascular diagnostic tests. These begin with cost-effective or cost-beneficial tests (e .g. venous duplex imaging) followed by those tests that are probably effective (as a result of their widespread application) with regard to accuracy. sensitivity/specificity and predictive value (e.g. segmental plethysmography). At the opposite end of the range are those tests that are possibly effective (e.g. magnetic resonance Ilowmetry), and those tests that are ineffective. based on the fact that they have been discarded or considered invalid (e.g. thermography). However. this categorisation is preliminary.
In this context, it is worth noting. given the prevalence of PVD among the Medicare popula-tion in the US, the question of reimbursement and the costs of undertaking vascular tests. Fillinger et al.ll-I.151 have considered the implications of the reimbursement rates under the previous Medicare Part B reimbursement system, the rates agreed upon under the more recent Resource-Based Relative-Value Scale (RBRVS) and the actual costs of performing noninvasive laboratory studies. They concluded that. with regard to the estimated national average costs incurred by both small and large laboratories (both hourly and case volume), reimbursement would be less than the actual costs incurred.
The cost effectiveness of magnetic resonance angiography has been evaluated for the preoperative planning of treatment in patients with limbthreatening PVD.l1olln that study. cost effectiveness was evaluated within a decision-model framework, with the incremental cost per quality-adjusted lifeyear gained with conventional angiography replaced or supplemented with the corresponding figure for magnetic resonance angiography. Given estimates of the accuracy of conventional and magnetic resonance angiography. the study authors l161 found that the cost impact of the latter ranged from a high of $US78 000 (in terms of cost savings) to situations of increased cost. With a base-case cost savings estimate of $US25 ~N5 (average patient treatment cost). the study authors 1lol concluded that magnetic resonance angiography is a possibly cost-effective alternative if its accuracy for the inIlow evaluation achieves certain threshold values: a sensitivity of 90 to 95 %-and a specificity of 85 to 86lk compared with conventional angiography.
Quality of Life
Atherosclerosis is the primary underlying cause of both coronary artery disease and peripheral vascular disorders . In addition to shortening life expectancy. atherosclerosis can have adverse health consequences that lead to dysfunction and decreased well-being. Therefore. in addition to lowering the risk of premature death. the primary goal of an intervention aimed at managi ng atherosclerotic complications should be improvement of the patient's current and future quality of life.
For healthcare providers, quality of life is increasingly being viewed as a therapeutic endpoint. An over-riding factor leading to this has been the gradual shift in the focus of primary medical care during the twentieth century from limiting mortality to limiting morbidity and the patient-reported impact of that morbidity. For those conditions that shorten life expectancy and for which there are no cures, managing symptoms and maintaining function and well-being should be the primary objectives of medical care.
The measurement of function and well-being, or quality of life, in the evaluation of pharmaceutical products and services has gained increasing attention.l 17 -19 ) However, like the economic literature regarding PVDs and pharmacotherapy, the QOL literature in this area is sparse. Therefore, this section of the review will provide an overview of the published literature that has addressed QOL issues associated with PVDs in general and, specifically, those associated with its treatment. The role of drug therapy in the treatment of peripheral vascular disorders is limited, and this fact is reflected in the lack of a substantial body of literature regarding it.
As observed by Gillings,[20) the terms PVD, PAD, peripheral arterial occlusive disease (PAOD), and chronic occlusive artery disease (COAD) are often used interchangeably. An attempt has been made to adhere to the specific terminology used in the articles under review; however, PVD will be used to refer to the general condition under study.
Intermittent claudication, the major symptom of PVD, is often the reason why individuals initially seek medical attention for this disease.J2°1 It is typified by muscle pain, cramping and fatigue brought on by exercise and relieved by rest. In advanced disease, pain during rest is present. Other symptoms of arterial insufficiency in the lower limbs include mottled and red skin, skin that is cool to the touch and/or has a shiny appearance, decreased e Adls Inlemaflonal Umlled. All rights reserved.
Lallgley & CoolIS hair growth, thickened toenails, and, sometimes, ischaemic uIcers.[2I)
The treatment of intermittent claudication depends on the stage of disease progression. For patients with recent-onset or mild chronic intermittent claudication, watchful waiting, reduction of risk factors, and exercise are the most frequent approaches. In particular, smokers should stop smoking, and patients with hypertension, hyperlipidaemia or diabetes mellitus should receive effective management of those conditions. Symptoms can remain mild for long periods of time. Drug therapy with pentoxifylline to reduce blood viscosity, and aspirin to reduce platelet adhesiveness, can be used in conjunction with exercise and modification of risk factors. [22) For more severely affected patients, procedures such as angioplasty and bypass grafting are used. If all else fails, amputation of the lower limbs may be necessary.
As is apparent from the symptoms and therapeutic approaches, PVD and its treatment are likely to have a major impact on the patient's functioning and well-being. Hunt and colleagues [23) provided one of the first published reports on the impact of PVD on quality of life. Their study was conducted in a group of patients who were attending an outpatient surgical clinic in the UK, and had either undergone surgery or been referred for possible surgical treatment. Based on data collection using the Nottingham Health Profile (NHP), the study authors [23[ concluded that quality of life was substantially impaired in these patients. Pain, sleep disturbances, mobility limitations, and low levels of energy were the most serious problems encountered.
In a more recent study, Crosby et al.
[221 used the General Well-Being Questionnaire (GWB) to investigate the self-reported health and well-being of a group of patients who were diagnosed with PAOD. The study patients were being treated at a Department of Veterans Affairs Medical Center in the US. The researchers [22[ found that the patients with PAOD reported lower overall scores (indicating poorer quality of life) on the GWB, and on the Pharmacoecooomics 1997 Mar; 11 (3) subcategories of general health. positive well-being, self-control and vitality. compared with a 'well population'. In addition to the items on the GWB, patients were asked to list their greatest concerns about having PYD. The top 3 concerns were pain from claudication, inability to walk, and amputation of the leg or foot. As with the report of Hunt et al.,I2-' 1 this study provided little more than a point-in-time description of the QOL impairments reported by patients with PYD.
Arfvidsson and colleaguesl~.jl measured quality of life using the Sickness Impact Profile (SIP) in 148 consecutive patients who presented at a Swedish outpatient clinic with symptoms of intermittent claudication. The aim of the study was to determine the extent to which intermittent claudication and the resulting reduction in walking ability influenced self-reported quality of life as measured by the SIP. The hope was that the SIP could be used to evaluate the overall dysfunction in patients with intermittent claudication in an effort to determine who may benefit from different interventions (i.e. no treatment, physical training, or surgical reconstruction). The majority of the SIP domains were shown to be useful in confirming objective dysfunction in patients with intermittent claudication. The true usefulness of the SIP in the process of selection among alternative treatment approaches remains to be determined. Albers et al. 1251 [ongitudinally assessed the qua[-ity of life of 3 cohorts of patients undergoing treatment for ischaemia associated with infrainguinal arterial occlusive disease. On the basis of initial treatment, the 6 [ patients were grouped into the following cohorts: conservative treatment (n = 31), arterial reconstruction (n = 14) and major amputation (n = [6) . Quality of life was measured using design, the treatment cohorts were not directly comparable. However, within-cohort (conservative treatment and arterial reconstruction) comparisons indicated that quality of life improved if major amputation was avoided, and is improved and sustained by a functioning graft.
Gibbons et at.l~71 compared patients' quality of life before and after infrainguinal revascularisation for PYD. Quality of life was assessed via scales from the Functional Status Questionnaire, 36-ltem Short-Form Questionnaire (SF-36), and conditionspecific items that were developed for the study. Six months after surgery, patient QOL measures showed improvements in functioning, mental well-being and vitality; symptoms were also improved. In addition, those patients who functioned better before the operation reported improved function and well-being 6 months after the operation. As with much of the literature in this area, a limitation of this study was the lack of a comparahIe control group that underwent an alternative treatment approach.
Amputation is the outcome of PYD that all the stakeholders wish to avoid. However, despite advances in arterial reconstructive surgery and angioplasty. the number of lower limb amputations resulting from the progression of PYD remain~ significant. 12X1 Pell et a[YlJl compared the quality of life of 149 patients who had undergone lower limb amputations as a result of PAD with that of an ageand sex-matched control group who had neither PAD nor undergone an amputation. On average, 38 months had passed between the last amputation and participation in this study.1 2Y I Based on the NHP, the patients who had undergone an amputation reported significantly more prohlems with mobility. social isolation. lethargy, pain, sleep and emotional disturbance than those in the control group. The authorsl~YI concluded that the poor quality of life following lower limb amputation for PAD was primarily the result of restricted mobility, which is not an unexpected finding .
Drug therapy is usually associated with the more conservative approaches to the treatment of PYD.
In his review of 2 clinical trials of pentoxifylline in patients with intermittent claudication, Gillings (20) stated that if the clinical outcome of the trials (i.e. treadmill improvements) is converted to comparable distances on flat ground, pentoxifylline appears to have the potential to improve quality of life in these patients. Patient-reported functioning and well-being (i.e. quality of life) was not an outcome in these trials. However, the lack of direct QOL assessment in trials of this type is a major oversight. Any intervention to slow, halt or reverse the progression of PVD should assess changes in quality of life.
In summary, no published studies were found that actually compared the QOL outcomes associated with alternative treatment approaches in comparable patients or that reported QOL changes associated with pharmacotherapy in patients with PVD. This is a major weakness and limitation in terms of the availability of useful comparative information as an input to decision-making regarding the appropriate treatment of PVD.
Conclusions
In the US, and particularly from the perspective of managed care as a principal purchaser of pharmaceutical products, there is increasing concern as to the relevance of published pharmacoeconomic studies to drug purchasing and formulary decisions. This concern is further fuelled by the increasing emphasis on disease-management interventions. Managed care is not concerned with simply identifying the costs of disease and therapy interventions within their delivery (and contractual) environment. Instead, it is concerned with assessing the options available to reduce costs through the targeting of programmes to patient and provider groups, in order to maintain or improve outcomes and quality of life, as well as meeting externally mandated standards for quality improvement and accreditation.
Clearly, pressures for cost containment are present in countries with national health systems. This is demonstrated by the increasing interest shown in disease-management interventions in these countries, which will prove singularly difficult to implement in such environments with limited data (compared with US claims data which are available to managed care organisations). However. the competitive pressures on health systems in the US. the pace of structural change in healthcare delivery. and the emphasis that is being put on disease management by healthcare divisions of pharmaceutical companies (including wholly owned disease management subsidiaries) and health systems. means that the question of the relevance of pharmacoeconomic studies to their resource allocation decisions is of particular concern in a US treating environment.
The present authors' experience in working with healthcare systems in the US, and in attempting to meet their drug information requirements for formulary decision-making. point quite clearly to the deficiencies in the existing state of pharmacoeconomics. Not only are many disease or therapy areas poorly served in terms of the number and quality of pharmacoeconomic studies -with PVD a good example -but the studies that exist are typically of limited applicability to healthcare decision-making.
As in the case of PVD. the single most important limitation in pharmacoeconomic studies is on the perspective taken. Few studies (and none in the area of PVD) take what may be described as a system or therapy intervention perspective. That is, they fail to consider the disease or treatment area as a whole. No attempt is made to consider treatment pathways and intervention options for that disease area, with an evaluation of alternative interventions (observation, lifestyle modification, surgery. devices or drugs) and the place of pharmaceutical products in such strategies.
The consideration of pentoxifylline therapy is a case in point. No known published pharmacoeconomic studies have considered the role of pentoxifylline in the treatment of arterial disease and compared it with alternative interventions such as surgery or placebo. Furthermore. no study has attempted to examine the costs of arterial disease, particularly in a managed-care environment, identifying the major cost drivers (medical services, drugs) for the principal treatment pathways, and considering the contribution of pentoxifylline to resource utilisation and patient outcomes. Unless this is done. studies (such as those hy Stergachis et alYI and Neels et alY'I) are of limited use in a managed-care environment. in which the concern is not only whether or not to admit/delete the drug to/from formulary, but to provide guidelines to providers (and treatment-cost benchmarks) for a more efficient delivery of healthcare interventions.
While it is important to evaluate the resourceutilisation impacts of sUbtherapeutic dosages of a drug, care must be taken to ensure that such resource impacts are evaluated in the context of the total costs of treatment in that disease area and that the analysis is presented in such a way that its conclusions can be translated to alternative treating environments. Such studies would be invaluahle when guidelines are being developed by healthcare groups in an attempt to improve the efficiency of healthcare delivery.
These comments should not be taken to detract from the quality of many of the studies that have been reviewed. Indeed. many of the elements of a system-impact assessment were included in the questions that have been addressed. These questions include: the choice of drug therapy; the costimplications of sub-therapeutic dosages; the questions of testing procedures (including their rationale and cost effectiveness): and issues of the most appropriate reimhursement strategy. The impact of reimbursement cost structures on the access to tests for prospectively high-risk and high-cost populations are also identified as important issues.
However. what is missing is a framework that. from a health-system perspective. brings these elements together and provides a basis on which a cost-consequences and a cost-outcomes assessment could be made. This would also provide an assessment of the impact to the health system of access to test procedures, the pricing of those pro-[ Adis International Umited. All rights reserved 235 cedures and the long term impact of a more integrated care delivery and management system for patients with PVD.
